120
Participants
Start Date
January 29, 2024
Primary Completion Date
February 1, 2026
Study Completion Date
March 1, 2026
Hydroxychloroquine
The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.
Sacituzumab Govitecan
Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them.
Trastuzumab Deruxtecan
Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
RECRUITING
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER